Analysts forecast that Voyager Therapeutics Inc (NASDAQ:VYGR) will report ($0.74) earnings per share (EPS) for the current quarter, Zacks reports. Three analysts have issued estimates for Voyager Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.92) and the highest estimate coming in at ($0.48). Voyager Therapeutics posted earnings of ($0.57) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 29.8%. The business is scheduled to issue its next quarterly earnings report on Wednesday, March 21st.
On average, analysts expect that Voyager Therapeutics will report full year earnings of ($2.99) per share for the current year, with EPS estimates ranging from ($3.20) to ($2.74). For the next fiscal year, analysts forecast that the firm will post earnings of ($2.98) per share, with EPS estimates ranging from ($4.16) to ($1.98). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of analysts that cover Voyager Therapeutics.
A number of research firms have issued reports on VYGR. BTIG Research began coverage on shares of Voyager Therapeutics in a report on Tuesday, December 19th. They issued a “buy” rating and a $32.00 target price on the stock. Piper Jaffray Companies restated an “overweight” rating and issued a $28.00 target price on shares of Voyager Therapeutics in a report on Tuesday, November 28th. Wedbush restated an “outperform” rating and issued a $26.00 target price (up from $22.00) on shares of Voyager Therapeutics in a report on Monday, November 20th. Canaccord Genuity set a $26.00 target price on shares of Voyager Therapeutics and gave the company a “buy” rating in a report on Wednesday, November 15th. Finally, Zacks Investment Research lowered shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, November 8th. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and eleven have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $26.90.
In other news, insider Bernard Ravina sold 5,490 shares of the company’s stock in a transaction dated Friday, November 10th. The shares were sold at an average price of $13.26, for a total transaction of $72,797.40. Following the completion of the transaction, the insider now owns 16,473 shares of the company’s stock, valued at approximately $218,431.98. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In the last ninety days, insiders have sold 21,960 shares of company stock valued at $370,850. Corporate insiders own 8.00% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. increased its position in Voyager Therapeutics by 3.2% during the 2nd quarter. Vanguard Group Inc. now owns 430,765 shares of the company’s stock worth $3,860,000 after purchasing an additional 13,194 shares in the last quarter. Wells Fargo & Company MN increased its position in Voyager Therapeutics by 312.8% during the 3rd quarter. Wells Fargo & Company MN now owns 377,190 shares of the company’s stock worth $7,766,000 after purchasing an additional 285,806 shares in the last quarter. Citadel Advisors LLC acquired a new stake in Voyager Therapeutics during the 3rd quarter worth approximately $5,155,000. DAFNA Capital Management LLC increased its position in Voyager Therapeutics by 187.2% during the 2nd quarter. DAFNA Capital Management LLC now owns 204,808 shares of the company’s stock worth $1,835,000 after purchasing an additional 133,488 shares in the last quarter. Finally, State Street Corp increased its position in Voyager Therapeutics by 11.8% during the 2nd quarter. State Street Corp now owns 184,526 shares of the company’s stock worth $1,653,000 after purchasing an additional 19,471 shares in the last quarter. 35.97% of the stock is owned by hedge funds and other institutional investors.
About Voyager Therapeutics
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.